Skip to main content

Table 1 Study group demographics

From: Association of ABI3 and PLCG2 missense variants with disease risk and neuropathology in Lewy body disease and progressive supranuclear palsy

Group Study population Total N Mean age ± SD Female
N %
LBD-NP Low 263 80.84 ± 11.13 128 48.67
Intermediate 287 79.63 ± 10.33 163 56.79
High 423 78.04 ± 7.92 268 63.36
Combined LBD-NP 973 79.27 ± 9.66 559 57.45
PSP PSP series 1 230 74.8 ± 7.06 105 45.65
PSP series 2 810 75.47 ± 7.45 376 46.42
Combined PSP 1040 75.32 ± 7.37 481 46.25
Controls   3351 80.6 ± 7.1 1844 55.03
  1. All LBD-NP and PSP participants had neuropathologic diagnosis. Controls had either clinical or neuropathologic diagnosis. “Combined LBD-NP” refers to the combined group of LBD-NP patients from all sub-categories. The sub-categories of “High”, “Intermediate”, or “Low” refers to the likelihood of diagnosing typical clinical DLB-CL based on the 2017 DLB-CL Consortium neuropathologic criteria [17]. All control and a subset of 230 PSP (series 1) cases were genotyped in our prior study [8]. All LBD-NP and an additional 810 PSP cases (series 2) were genotyped in this study
  2. PSP progressive supranuclear palsy, LBD-NP Lewy body disease, neuropathologic diagnosis